Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of ASP1128 in Healthy Adults and Elderly
NCT04742517Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP1128 in acute kidney injury (AKI) (4 arms), sponsored by Astellas Pharma. Primary endpoints: Number of participants with Adverse Events (AEs), Number of participants with laboratory value abnormalities and/or AEs and 3 more. Started Nov 2017; status: completed.
02
Drugs
ASP1128
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04742517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742517.